Acquisitions29 Jun 2026, 10:40 pm
Biocon Completes BBL Acquisition, Makes it Wholly-Owned Subsidiary
AI Summary
Biocon Ltd has successfully acquired an additional 1,15,36,956 equity shares of its material subsidiary, Biocon Biologics Limited (BBL), from 127 selling shareholders. This acquisition was completed on June 29, 2026, through a preferential issue of 87,86,362 equity shares of Biocon Ltd at an issue price of ₹376.41 per share. The transaction effectively makes BBL a wholly-owned subsidiary of Biocon Ltd. The company's issued and paid-up equity share capital has increased following this allotment.
Key Highlights
- Biocon Ltd acquired 1,15,36,956 equity shares of Biocon Biologics Limited.
- BBL is now a wholly-owned subsidiary of Biocon Ltd.
- Acquisition was funded by issuing 87,86,362 Biocon shares.
- The issue price for new shares was ₹376.41 per equity share.
- Biocon's equity share capital increased post-transaction.
Price Impact
More from BIOCON